BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 29355391)

  • 1. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
    Arch Pathol Lab Med; 2018 Mar; 142(3):321-346. PubMed ID: 29355391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
    J Mol Diagn; 2018 Mar; 20(2):129-159. PubMed ID: 29398453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
    J Thorac Oncol; 2018 Mar; 13(3):323-358. PubMed ID: 29396253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
    Kalemkerian GP; Narula N; Kennedy EB; Biermann WA; Donington J; Leighl NB; Lew M; Pantelas J; Ramalingam SS; Reck M; Saqi A; Simoff M; Singh N; Sundaram B
    J Clin Oncol; 2018 Mar; 36(9):911-919. PubMed ID: 29401004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
    Arch Pathol Lab Med; 2013 Jun; 137(6):828-60. PubMed ID: 23551194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
    J Thorac Oncol; 2013 Jul; 8(7):823-59. PubMed ID: 23552377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M; College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology
    J Mol Diagn; 2013 Jul; 15(4):415-53. PubMed ID: 23562183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
    Leighl NB; Rekhtman N; Biermann WA; Huang J; Mino-Kenudson M; Ramalingam SS; West H; Whitlock S; Somerfield MR
    J Clin Oncol; 2014 Nov; 32(32):3673-9. PubMed ID: 25311215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
    Kalemkerian GP; Narula N; Kennedy EB
    J Oncol Pract; 2018 May; 14(5):323-327. PubMed ID: 29589987
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.
    Sepulveda AR; Hamilton SR; Allegra CJ; Grody W; Cushman-Vokoun AM; Funkhouser WK; Kopetz SE; Lieu C; Lindor NM; Minsky BD; Monzon FA; Sargent DJ; Singh VM; Willis J; Clark J; Colasacco C; Bryan Rumble R; Temple-Smolkin R; B Ventura C; Nowak JA
    Arch Pathol Lab Med; 2017 May; 141(5):625-657. PubMed ID: 28165284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer.
    Bartley AN; Mills AM; Konnick E; Overman M; Ventura CB; Souter L; Colasacco C; Stadler ZK; Kerr S; Howitt BE; Hampel H; Adams SF; Johnson W; Magi-Galluzzi C; Sepulveda AR; Broaddus RR
    Arch Pathol Lab Med; 2022 Oct; 146(10):1194-1210. PubMed ID: 35920830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
    Hanna NH; Robinson AG; Temin S; Baker S; Brahmer JR; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Moffitt PR; Phillips T; Riely GJ; Rosell R; Schiller JH; Schneider BJ; Singh N; Spigel DR; Tashbar J; Masters G
    J Clin Oncol; 2021 Mar; 39(9):1040-1091. PubMed ID: 33591844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
    Cagle PT; Raparia K; Portier BP
    Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.
    Sepulveda AR; Hamilton SR; Allegra CJ; Grody W; Cushman-Vokoun AM; Funkhouser WK; Kopetz SE; Lieu C; Lindor NM; Minsky BD; Monzon FA; Sargent DJ; Singh VM; Willis J; Clark J; Colasacco C; Rumble RB; Temple-Smolkin R; Ventura CB; Nowak JA
    J Clin Oncol; 2017 May; 35(13):1453-1486. PubMed ID: 28165299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.
    Prabhash K; Advani SH; Batra U; Biswas B; Chougule A; Ghosh M; Muddu VK; Sahoo TP; Vaid AK
    Adv Ther; 2019 Apr; 36(4):766-785. PubMed ID: 30864106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
    J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (
    Tang Z; Wang L; Tang G; Medeiros LJ
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.